سعر Eupifiban 12.5mg/50ml i.v.infusion 2022

Tirofiban 12.5 mg/50 ml (250 micrograms/ml) concentrate for IV infusion, 50 ml vial (Eupifiban; Hikma Specialized Pharmaceuticals).

• Prevention of early myocardial infarction in adults with non-ST-elevation acute coronary syndrome (NSTE-ACS) with the last episode of chest pain within 12 hours and ECG changes and/or elevated cardiac enzymes.Population: Adultselectronic medicines compendium (eMC), United Kingdom
• Reduction of major cardiovascular events in adults with acute myocardial infarction intended for primary PCI (with ASA and unfractionated heparin).Population: Adultselectronic medicines compendium (eMC), United Kingdom

• Bleeding is the most common adverse reaction (usually mild mucocutaneous or catheter-site bleeding; serious GI, retroperitoneal and intracranial bleeding reported; fatal bleeding possible). Thrombocytopenia (<90,000/mm3) in 1.5% of patients; nausea 1.7%, fever 1.5%, headache 1.1%; severe allergic reactions including anaphylaxis.International label, same formulation · electronic medicines compendium (eMC), United Kingdom

• Hypersensitivity to tirofiban or any excipient, or thrombocytopenia during earlier use of a GP IIb/IIIa receptor antagonist.International label, same formulation · electronic medicines compendium (eMC), United Kingdom
• Stroke within 30 days or any history of haemorrhagic stroke; known intracranial disease (neoplasm, arteriovenous malformation, aneurysm); active or recent (within 30 days) clinically relevant bleeding; malignant hypertension; relevant trauma or major surgery within six weeks.International label, same formulation · electronic medicines compendium (eMC), United Kingdom
• Thrombocytopenia (platelets <100,000/mm3) or platelet function disorders; clotting disturbances (prothrombin time >1.3 times normal or INR >1.5); severe liver failure.International label, same formulation · electronic medicines compendium (eMC), United Kingdom

• Not recommended without unfractionated heparin; limited experience with enoxaparin. Not recommended with thrombolytic therapy, recent CPR/biopsy/lithotripsy, active peptic ulcer within 3 months, uncontrolled hypertension (>180/110 mmHg), acute pericarditis, vasculitis, suspected aortic dissection, haemorrhagic retinopathy or occult GI/urinary bleeding. Stop immediately if thrombolysis, emergency CABG or an intra-aortic balloon pump is needed.International label, same formulation · electronic medicines compendium (eMC), United Kingdom
• Bleeding risk is higher in elderly, female and low-body-weight patients and with creatinine clearance <60 ml/min; minimise vascular punctures, use only compressible access sites and monitor the femoral sheath site closely.International label, same formulation · electronic medicines compendium (eMC), United Kingdom

• Other antiplatelet agents, heparin, warfarin and thrombolyticsCombined use with other platelet aggregation inhibitors, heparin, warfarin or thrombolytics increases the risk of bleeding; monitor haemostasis regularly. Not recommended with thrombolytic therapy or other parenteral GP IIb/IIIa inhibitors.electronic medicines compendium (eMC), United Kingdom

• No or limited data in pregnant women and animal studies are insufficient; not recommended during pregnancy unless clearly necessary.International label, same formulation · electronic medicines compendium (eMC), United Kingdom
• Unknown whether excreted in human milk; excreted in animal milk. Decide whether to discontinue breastfeeding or tirofiban therapy.International label, same formulation · electronic medicines compendium (eMC), United Kingdom

• Tirofiban: Reversible antagonist of fibrinogen binding to the platelet GP IIb/IIIa receptor, inhibiting platelet aggregation (US AGGRASTAT label).